Safety, immunovirological, and CNS effects of PD-1 inhibition in people with HIV without malignancy.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
a single dose of pembrolizumab to assess safety and effects on immune, virologic, and CNS parameters
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
HIV immune responses and viral loads were unchanged, although transient CSF viral increases occurred in two participants. A single dose pembrolizumab appears safe, supporting evaluation of repeated dosing.
Checkpoint inhibitors are being explored for chronic central nervous system (CNS) infections such as HIV, but safety data in the absence of malignancy are limited.
APA
Reoma LB, Johnson TP, et al. (2026). Safety, immunovirological, and CNS effects of PD-1 inhibition in people with HIV without malignancy.. The Journal of infectious diseases. https://doi.org/10.1093/infdis/jiag127
MLA
Reoma LB, et al.. "Safety, immunovirological, and CNS effects of PD-1 inhibition in people with HIV without malignancy.." The Journal of infectious diseases, 2026.
PMID
41797330 ↗
Abstract 한글 요약
Checkpoint inhibitors are being explored for chronic central nervous system (CNS) infections such as HIV, but safety data in the absence of malignancy are limited. In this phase I, non-randomized study, six virally suppressed individuals with HIV received a single dose of pembrolizumab to assess safety and effects on immune, virologic, and CNS parameters. Over 12 months, 29 adverse events occurred, all grade 1-2, with no serious events. HIV immune responses and viral loads were unchanged, although transient CSF viral increases occurred in two participants. A single dose pembrolizumab appears safe, supporting evaluation of repeated dosing.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Suppressor of cytokine signaling (SOCS) proteins in human retroviral infections.
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.
- A case report of breast cancer recurrence with cystitis: the impact of immune checkpoint inhibitor therapy on the incidence of cystitis.
- Synchronous occurrence of interstitial lung disease and ICANS after tarlatamab initiation in recurrent small-cell lung cancer.
- Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.